Jesse D Vrecenak
Overview
Explore the profile of Jesse D Vrecenak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
179
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Swanson K, Phelps H, Grant M, Lang E, Warner B, Vrecenak J
Transpl Immunol
. 2025 Feb;
89:102200.
PMID: 39961392
In utero hematopoietic cell transplantation (IUHCT) exploits tolerogenic fetal immunologic development to facilitate engraftment of donor. Non-hematopoietic donor-derived cells have been described in both in-utero and post-natal models of hematopoietic...
2.
Grant M, Nelvagal H, Tecos M, Hamed A, Swanson K, Cooper J, et al.
Commun Biol
. 2024 Dec;
7(1):1624.
PMID: 39638879
In utero hematopoietic cell transplantation (IUHCT) utilizes fetal immune tolerance to achieve durable chimerism without conditioning or immunosuppression during a unique window in fetal development. Though donor cells have been...
3.
Grant M, MacGregor R, Vrecenak J
Am Surg
. 2022 Oct;
89(11):4758-4763.
PMID: 36269345
Background: Many patients with suspected appendicitis are initially evaluated at outlying hospitals and then transferred to a tertiary care pediatric hospital for surgical management. We sought to evaluate whether diagnosis...
4.
Wilson D, Hoefgen H, Vrecenak J
J Pediatr Adolesc Gynecol
. 2022 Jan;
35(3):411-412.
PMID: 34973456
No abstract available.
5.
Grant M, Wilson N, Keller M, Huguenard A, Strahle J, Vrecenak J
Childs Nerv Syst
. 2021 Jan;
37(8):2719-2722.
PMID: 33388923
Background: Ventriculoperitoneal (VP) shunts are the most common treatment for hydrocephalus in both pediatric and adult patients. Complications resulting from the abdominal portion of shunts include tube disconnection, obstruction of...
6.
Grant M, Vrecenak J
J Surg Res
. 2020 Sep;
257:462-467.
PMID: 32896814
Background: In utero hematopoietic cell transplantation (IUHCT) has been demonstrated to reliably generate chimeric offspring. This technique introduces transplanted cells into a fetus while the immune system is still developing,...
7.
Loukogeorgakis S, Fachin C, Dias A, Li H, Tang L, Kim A, et al.
Blood
. 2019 Oct;
134(22):1983-1995.
PMID: 31570489
Host cell competition is a major barrier to engraftment after in utero hematopoietic cell transplantation (IUHCT). Here we describe a cell-engineering strategy using glycogen synthase kinase-3 (GSK3) inhibitor-loaded nanoparticles conjugated...
8.
Vrecenak J, Partridge E, Pearson E, Flake A
Biol Blood Marrow Transplant
. 2019 Sep;
26(1):e21-e24.
PMID: 31493540
The rationale for in utero hematopoietic cell transplantation (IUHCT) rests on exploitation of normal events during hematopoietic and immunologic ontogeny to allow allogeneic hematopoietic engraftment without myeloablative conditioning. Host hematopoietic...
9.
Vrecenak J, Pearson E, Todorow C, Li H, Johnson M, Flake A
Biol Blood Marrow Transplant
. 2018 May;
24(9):1795-1801.
PMID: 29802901
In utero hematopoietic cell transplantation (IUHCT) offers the potential to achieve allogeneic engraftment and associated donor-specific tolerance without the need for toxic conditioning, as we have previously demonstrated in the...
10.
Partridge E, Davey M, Hornick M, McGovern P, Mejaddam A, Vrecenak J, et al.
Nat Commun
. 2017 May;
8:15794.
PMID: 28534492
This corrects the article DOI: 10.1038/ncomms15112.